Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts

G. Lombardi, G. Gramegna, C. Cavanna, G. Poma, E. Marangoni, G. Michelone

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.

Original languageEnglish
Pages (from-to)31-34
Number of pages4
JournalMycopathologia
Volume106
Issue number1
DOIs
Publication statusPublished - Apr 1989

Fingerprint

Itraconazole
itraconazole
amphotericin B
Amphotericin B
Yeasts
yeasts
Candida kefyr
Meyerozyma guilliermondii
Pharmaceutical Preparations
Candida glabrata
Candida parapsilosis
Glucose
Candida tropicalis
glucose
triazoles
Cryptococcus neoformans
antifungal agents
Triazoles
new drugs
dimethyl sulfoxide

Keywords

  • amphotericin B
  • itraconazole
  • susceptibility testing
  • yeast infections

ASJC Scopus subject areas

  • Plant Science
  • Agricultural and Biological Sciences (miscellaneous)

Cite this

Itraconazole vs amphotericin B : in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts. / Lombardi, G.; Gramegna, G.; Cavanna, C.; Poma, G.; Marangoni, E.; Michelone, G.

In: Mycopathologia, Vol. 106, No. 1, 04.1989, p. 31-34.

Research output: Contribution to journalArticle

@article{343e8b4ba965462599ed3d0f6d9e9a14,
title = "Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts",
abstract = "Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5{\%}, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5{\%} glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.",
keywords = "amphotericin B, itraconazole, susceptibility testing, yeast infections",
author = "G. Lombardi and G. Gramegna and C. Cavanna and G. Poma and E. Marangoni and G. Michelone",
year = "1989",
month = "4",
doi = "10.1007/BF00436923",
language = "English",
volume = "106",
pages = "31--34",
journal = "Mycopathologia",
issn = "0301-486X",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Itraconazole vs amphotericin B

T2 - in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts

AU - Lombardi, G.

AU - Gramegna, G.

AU - Cavanna, C.

AU - Poma, G.

AU - Marangoni, E.

AU - Michelone, G.

PY - 1989/4

Y1 - 1989/4

N2 - Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.

AB - Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.

KW - amphotericin B

KW - itraconazole

KW - susceptibility testing

KW - yeast infections

UR - http://www.scopus.com/inward/record.url?scp=0024399245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024399245&partnerID=8YFLogxK

U2 - 10.1007/BF00436923

DO - 10.1007/BF00436923

M3 - Article

C2 - 2549421

AN - SCOPUS:0024399245

VL - 106

SP - 31

EP - 34

JO - Mycopathologia

JF - Mycopathologia

SN - 0301-486X

IS - 1

ER -